As an innovative artificial small-molecule inhibitor that can suppress both the PI3K/Akt/mTOR signaling pathway and HDACs, CUDC-907 has been reported to activate autophagy in ESCC cells by suppressing the PI3K/Akt/mTOR signaling pathway or LCN2 to induce accumulation of ROS, suggesting a potential targeted therapy option for patients with EC 145. Here, AKT1 is linked to esophageal squamous cell carcinoma.